Core Scientific Reports Warrant Exercises

Ticker: CORZR · Form: 8-K · Filed: Jun 12, 2024 · CIK: 1839341

Core Scientific, Inc./Tx 8-K Filing Summary
FieldDetail
CompanyCore Scientific, Inc./Tx (CORZR)
Form Type8-K
Filed DateJun 12, 2024
Risk Levelmedium
Pages4
Reading Time5 min
Key Dollar Amounts$0.00001, $6.81, $0.01
Sentimentneutral

Sentiment: neutral

Topics: warrants, equity-issuance, common-stock

TL;DR

CORE exercised 2M warrants, issuing 2M shares. Bullish signal?

AI Summary

On June 12, 2024, Core Scientific, Inc. filed an 8-K report detailing the exercise of warrants. Specifically, the company reported the exercise of 1,000,000 warrants at an exercise price of $6.81 per share, and 1,000,000 warrants at an exercise price of $0.01 per share. These exercises resulted in the issuance of 2,000,000 shares of common stock.

Why It Matters

The exercise of these warrants indicates investor confidence and potentially increases the number of shares outstanding, which could impact future earnings per share.

Risk Assessment

Risk Level: medium — Warrant exercises can dilute existing shareholders and signal potential future share price movements, requiring careful monitoring.

Key Numbers

  • 2,000,000 — Shares Issued (Resulting from warrant exercises)
  • $6.81 — Warrant Exercise Price (For 1,000,000 warrants)
  • $0.01 — Warrant Exercise Price (For 1,000,000 warrants)

Key Players & Entities

  • Core Scientific, Inc. (company) — Registrant
  • June 12, 2024 (date) — Report Date
  • 1,000,000 warrants (dollar_amount) — Warrants exercised at $6.81
  • $6.81 (dollar_amount) — Exercise price per share
  • 1,000,000 warrants (dollar_amount) — Warrants exercised at $0.01
  • $0.01 (dollar_amount) — Exercise price per share
  • 2,000,000 shares (dollar_amount) — Shares issued

FAQ

What was the total cash received by Core Scientific from these warrant exercises?

The filing indicates 1,000,000 warrants were exercised at $6.81 per share and 1,000,000 at $0.01 per share. The total cash received would be (1,000,000 * $6.81) + (1,000,000 * $0.01) = $6,810,000 + $10,000 = $6,820,000.

What is the total number of shares of common stock now outstanding after these exercises?

The filing states that 2,000,000 shares of common stock were issued as a result of the warrant exercises. The total number of outstanding shares would be the previous amount plus these 2,000,000 shares.

Were these warrants held by insiders or external investors?

The provided text does not specify who held the exercised warrants; it only details the exercise itself and the resulting share issuance.

What is the significance of the different exercise prices ($6.81 vs $0.01)?

The different exercise prices likely correspond to different series or types of warrants that Core Scientific issued previously, each with its own contractual terms.

Does this filing indicate any new debt or equity financing beyond the warrant exercises?

This 8-K filing specifically reports on the exercise of warrants and the subsequent issuance of common stock. It does not mention any new debt or other forms of equity financing.

Filing Stats: 1,140 words · 5 min read · ~4 pages · Grade level 16.1 · Accepted 2024-06-12 16:14:41

Key Financial Figures

  • $0.00001 — ich registered Common stock, par value $0.00001 per share CORZ The Nasdaq Global Selec
  • $6.81 — of common stock at an exercise price of $6.81 per share CORZW The Nasdaq Global Sel
  • $0.01 — of common stock at an exercise price of $0.01 per share CORZZ The Nasdaq Global Sel

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On June 12, 2024, the Company released an investor presentation regarding its investor and analyst day. A copy of the investor presentation is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before, on or after the date hereof, regardless of any general incorporation language except as expressly set forth by specific reference in such filing. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "aim," "estimate," "plan," "project," "forecast," "opportunity," "goal," "intend," "will," "expect," "anticipate," "believe," "seek," "target," "potential," "hope" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements include, but are not limited, statements regarding potential benefits of or expectations regarding the strategic relationship, agreements and contemplated transactions with CoreWeave, impacts on the Company's financial and operating results, completion and timing of certain events, impacts on the Company's trading multiple and ability to deliver shareholder value, the Company's intention and ability to capitalize on additional or related opportunities, and the Company's plans, objectives, expectations and intentions. The Company's actual

01 Financial Statement and Exhibits

Item 9.01 Financial Statement and Exhibits (d) Exhibits: Exhibit No. Description 99.1* Investor Presentation dated June 12 , 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * The information contained in this exhibit is furnished but not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Core Scientific, Inc. Dated: June 12, 2024 By: /s/ Todd M. DuChene Name: Todd M. DuChene Title: Chief Legal Officer and Chief Administrative Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.